Jurczak, Wojciech

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 1,685

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Thieblemont, C., Phillips, T., Ghesquieres, H., Cheah, C. Y., Clausen, M. R., Cunningham, D., Do, Y. R., Feldman, T., Gasiorowski, R., Jurczak, W., et al. (2023) · Journal of Clinical Oncology

Lymphoma Diagnosis and TreatmentCAR-T cell therapy research

Cited by 584

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J., Lamy, T., Morschhauser, F., et al. (2018) · The Lancet

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 453

Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

Linton, K. M., Vitolo, U., Jurczak, W., Lugtenburg, P. J., Gyan, E., Sureda, A., Christensen, J. H., Hess, B., Tilly, H., Cordoba, R., et al. (2024) · The Lancet Haematology

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 171

ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R2‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma

Vitolo, U., Witzig, T. E., Gascoyne, R. D., Scott, D. W., Zhang, Q., Jurczak, W., Özcan, M., Hong, X., Zhu, J., Jin, J., et al. (2019) · Hematological Oncology

Lymphoma Diagnosis and TreatmentViral-associated cancers and disorders

Cited by 84

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.

Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., et al. (2026) · The Lancet

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 41

Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1

Vose, J. M., Feldman, T., Chamuleau, M. E. D., Kim, W. S., Lugtenburg, P., Kim, T. M., Costa, P. A., Cheah, C. Y., Glimelius, I. C., Hess, B., et al. (2023) · Blood

Lymphoma Diagnosis and TreatmentCAR-T cell therapy research

Cited by 14

Characterization of Mechanisms of Resistance in Previously Treated Chronic Lymphocytic Leukemia (CLL) From a Head‐to‐Head Trial of Acalabrutinib Versus Ibrutinib

Woyach, J. A., Jones, D., Jurczak, W., Robak, T., Illés, A., Kater, A. P., Ghia, P., Byrd, J. C., Seymour, J. F., Long, S., et al. (2023) · Hematological Oncology

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 12

EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL

Vose, J., Vitolo, U., Lugtenburg, P., Chamuleau, M. E. D., Linton, K. M., Thieblemont, C., Sonnevi, K., Jurczak, W., Olszewski, A. J., Awan, F. T., et al. (2024) · Journal of Clinical Oncology

Lymphoma Diagnosis and TreatmentCAR-T cell therapy research

Cited by 10